Saturday 17 October 2026
Export GELS’s income statement to Excel — free account
Gelteq Limited
GELS Healthcare Drug Manufacturers Specialty & Generic
Gelteq Limited’s revenue for fiscal 2025 (year ended June 2025) was $368,500.00, up 282.7% from fiscal 2024.
0.45
0.02
+4.65%
Follow GELS
| Older periods | Jun '24 | Dec '24 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
Current Ratio |
+2 more quarters Free account |
0.08 | 0.79 | 0.27 | 0.09 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
18.52% | 15.52% | 19.64% | 25.41% | |
Debt/Equity |
0.25 | 0.21 | 0.27 | 0.36 | |
Asset Turnover |
— | — | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Intangible Assets out of Total Assets |
0.98 | 0.80 | 0.92 | 0.96 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(0.20) | (2.34) | (3.58) | (0.71) | |
Working Capital |
(2.34) | (0.87) | (2.67) | (3.50) | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | (0.05) | |
Net Current Asset Value |
(3.50) | (0.90) | (2.70) | (3.54) | |
| Other line items | |||||
Quick Ratio |
0.05 | 0.53 | 0.14 | 0.07 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
— | — | 0.27 | 0.18 | |
Average Payables |
— | — | 0.58 | 0.64 | |
Average Assets |
— | — | 14.53 | 13.58 | |
Average Common Equity |
— | — | 11.40 | 10.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Oct 2026